| Segment Information |
The Company operates in three reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results by reportable segment: Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold. | | | | | | Pharmaceutical | | | | | | | | | | | | | | and | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Three Months Ended June 30, 2018 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 6,689 | | | 126 | | $ | 57,019 | | $ | 63,834 | | | Direct cost of goods | | | (1,668) | | | | | | | | | (1,668) | | | Sales and marketing costs | | | (2,910) | | | | | | | | | (2,910) | | | Research and development | | | | | | (17,489) | | | | | | (17,489) | | | General and administrative | | | (383) | | | (9,763) | | | | | | (10,146) | | | National expenses | | | | | | | | | (56,218) | | | (56,218) | | | Segment income (loss) from operations | | | 1,728 | | | (27,126) | | | 801 | | | (24,597) | | | Segment assets | | $ | 11,307 | | $ | 159,763 | | | 65,796 | | $ | 236,866 | |
| | | | | | Pharmaceutical | | | | | | | | | | | | | | And | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Three Months Ended June 30, 2017 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 4,054 | | $ | 350 | | $ | 46,293 | | $ | 50,697 | | | Direct cost of goods | | | (878) | | | | | | | | | (878) | | | Sales and marketing costs | | | (2,610) | | | | | | | | | (2,610) | | | Research and development | | | | | | (13,483) | | | | | | (13,483) | | | General and administrative | | | (293) | | | (8,231) | | | | | | (8,524) | | | National expenses | | | | | | | | | (48,395) | | | (48,395) | | | Segment loss from operations | | | 273 | | | (21,364) | | | (2,102) | | | (23,193) | | | Segment assets | | $ | 5,447 | | $ | 167,787 | | $ | 76,612 | | $ | 249,846 | |
| | | | | | Pharmaceutical | | | | | | | | | | | | | | And | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Six Months Ended June 30, 2018 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 12,198 | | $ | 520 | | $ | 106,541 | | $ | 119,259 | | | Direct cost of goods | | | (3,140) | | | | | | | | | (3,140) | | | Sales and marketing costs | | | (5,670) | | | | | | | | | (5,670) | | | Research and development | | | | | | (42,544) | | | | | | (42,544) | | | General and administrative | | | (783) | | | (20,151) | | | | | | (20,934) | | | National expenses | | | | | | | | | (107,054) | | | (107,054) | | | Segment loss from operations | | $ | 2,605 | | | (62,175) | | $ | (513) | | $ | (60,083) | | | Segment assets | | $ | 11,307 | | | 159,763 | | $ | 65,796 | | $ | 236,866 | |
| | | | | | Pharmaceutical | | | | | | | | | | | | | | And | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Six Months Ended June 30, 2017 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 6,139 | | $ | 1,043 | | $ | 88,197 | | $ | 95,379 | | | Direct cost of goods | | | (1,347) | | | - | | | - | | | (1,347) | | | Sales and marketing costs | | | (4,877) | | | - | | | - | | | (4,877) | | | Research and development | | | | | | (21,887) | | | - | | | (21,887) | | | General and administrative | | | (612) | | | (15,897) | | | - | | | (16,509) | | | National expenses | | | - | | | - | | | (91,529) | | | (91,529) | | | Segment income (loss) from operations | | $ | (697) | | $ | (36,741) | | $ | (3,332) | | $ | (40,770) | | | Segment assets | | $ | 5,447 | | $ | 167,787 | | $ | 76,612 | | $ | 249,846 |
|
|